Subscribe
Subscribe today to receive CGD’s latest newsletters and topic updates.
All Commentary
Filters:
Topics
Facet Toggle
Content Type
Facet Toggle
Blog Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
October 04, 2022
Most R&D money flows from the private sector, which aims to maximize returns on investment. As a result, health R&D largely skews towards rich countries’ priorities and health system technical capacities, leaving significant gaps in diseases that primarily affect poor and marginalized populations.
Blog Post
September 26, 2022
Antimicrobial resistance is a major global problem. Today, drug resistant infections kill an estimated 1.27 million people per year, and low- and middle-income countries bear the brunt of AMR-related deaths and illness. Changing how we buy antimicrobials can help solve the problem.
Blog Post
June 28, 2022
CGD has set up a working group to examine different ways to purchase antimicrobials in LMICs in order to identify actionable policies to improve access and stewardship for key products and increase funding for research into new ones. We are launching today the Working Group’s first working paper.
Blog Post
June 10, 2022
In June 2021, Dr. Tedros Ghebreyesus, offered a challenge to the world: “To truly end the pandemic, our goal must be to vaccinate at least 70 percent of the world’s population by the time you meet again in Germany next year.” However, as we approach this year’s G7 summit, the 70 percent target has b...
Blog Post
June 02, 2022
In May, the World Bank issued a white paper on a new financial intermediary fund (FIF) for pandemic prevention, preparedness, and response. This document will be the basis for subsequent discussion and approval by the World Bank’s Board, composed of 25 constituencies representing 189 country governm...